GI Innovation

Sentiment around initial public offerings (IPOs) appears to be slowly recovering in South Korea as the market stabilizes somewhat amid ongoing political uncertainties at home and abroad. A couple of b

With the launch of novel lung cancer drug Leclaza (lazertinib) in South Korea and other international approvals in sight, Yuhan Corporation is at the starting point of potentially evolving into a co

South Korean bioventures have experienced a harsh financing environment in 2023 stemming from economic depression, high interest rates and a general deterioration in investor sentiment. Although most

2023 is wrapping up on a more positive note in terms of biopharma alliances involving South Korean companies. For the majority of this year, sentiment has been bleak amid an absence of major deals wit